Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOKITO-2B study of tenofovir bone and kidney toxicity in chronic hepatitis B
NL-OMON35281Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (4 arms), sponsored by Erasmus MC. Primary endpoints: Prevalence and incidence of renal insufficiency and kidney proximal tubular dysfunction and Reversibility after tenofovir dose reduction. Planned start Jan 2012; status: not yet recruiting.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON35281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35281.